MA45984B1 - Polytherapie pour la copd - Google Patents
Polytherapie pour la copdInfo
- Publication number
- MA45984B1 MA45984B1 MA45984A MA45984A MA45984B1 MA 45984 B1 MA45984 B1 MA 45984B1 MA 45984 A MA45984 A MA 45984A MA 45984 A MA45984 A MA 45984A MA 45984 B1 MA45984 B1 MA 45984B1
- Authority
- MA
- Morocco
- Prior art keywords
- copd
- combination therapy
- formoterol
- moderate
- prevention
- Prior art date
Links
- 238000002648 combination therapy Methods 0.000 title 1
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 abstract 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- VPNYRYCIDCJBOM-UHFFFAOYSA-M Glycopyrronium bromide Chemical compound [Br-].C1[N+](C)(C)CCC1OC(=O)C(O)(C=1C=CC=CC=1)C1CCCC1 VPNYRYCIDCJBOM-UHFFFAOYSA-M 0.000 abstract 1
- 239000000443 aerosol Substances 0.000 abstract 1
- 229950000210 beclometasone dipropionate Drugs 0.000 abstract 1
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 abstract 1
- 229960002848 formoterol Drugs 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 229960002462 glycopyrronium bromide Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0001—Details of inhalators; Constructional features thereof
- A61M15/0021—Mouthpieces therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0065—Inhalators with dosage or measuring devices
- A61M15/0068—Indicating or counting the number of dispensed doses or of remaining doses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/20—Valves specially adapted to medical respiratory devices
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pain & Pain Management (AREA)
- Dispersion Chemistry (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- External Artificial Organs (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Des formulations d'aérosol comprenant du bromure de glycopyrronium, du formotérol ou un sel de celui-ci, et du dipropionate de béclométasone sont utiles pour la prévention ou le traitement de la bronchopneumopathie chronique obstructive modérée/sévère.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16184608 | 2016-08-17 | ||
PCT/EP2017/070850 WO2018033598A1 (fr) | 2016-08-17 | 2017-08-17 | Polythérapie de la bronchopneumopathie chronique obstructive |
Publications (2)
Publication Number | Publication Date |
---|---|
MA45984A MA45984A (fr) | 2021-04-28 |
MA45984B1 true MA45984B1 (fr) | 2023-11-30 |
Family
ID=56740118
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA45984A MA45984B1 (fr) | 2016-08-17 | 2017-08-17 | Polytherapie pour la copd |
Country Status (30)
Country | Link |
---|---|
US (1) | US10098837B2 (fr) |
EP (1) | EP3500241B1 (fr) |
JP (1) | JP7384666B2 (fr) |
KR (1) | KR102440850B1 (fr) |
CN (1) | CN109562061A (fr) |
AU (1) | AU2017314153B2 (fr) |
BR (1) | BR112019003173A2 (fr) |
CA (1) | CA3029481A1 (fr) |
DK (1) | DK3500241T3 (fr) |
EA (1) | EA201990514A1 (fr) |
ES (1) | ES2961242T3 (fr) |
FI (1) | FI3500241T3 (fr) |
GE (1) | GEP20227418B (fr) |
HR (1) | HRP20231729T1 (fr) |
HU (1) | HUE064623T2 (fr) |
IL (1) | IL264612B2 (fr) |
LT (1) | LT3500241T (fr) |
MA (1) | MA45984B1 (fr) |
MD (1) | MD3500241T2 (fr) |
MX (1) | MX2019001587A (fr) |
NZ (1) | NZ750214A (fr) |
PH (1) | PH12019500315A1 (fr) |
PL (1) | PL3500241T3 (fr) |
PT (1) | PT3500241T (fr) |
RS (1) | RS64751B1 (fr) |
SG (1) | SG11201900471VA (fr) |
SI (1) | SI3500241T1 (fr) |
UA (1) | UA123231C2 (fr) |
WO (1) | WO2018033598A1 (fr) |
ZA (1) | ZA201900239B (fr) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060257324A1 (en) | 2000-05-22 | 2006-11-16 | Chiesi Farmaceutici S.P.A. | Pharmaceutical solution formulations for pressurised metered dose inhalers |
DK2515855T6 (da) | 2009-12-23 | 2023-06-06 | Chiesi Farm Spa | Kombinationsterapi til COPD |
US10098837B2 (en) | 2016-07-28 | 2018-10-16 | Chiesi Farmaceutici S.P.A. | Combination therapy for COPD |
CN112438966B (zh) * | 2019-08-30 | 2022-08-26 | 四川普锐特药业有限公司 | 一种医用定量吸入气雾剂 |
US20220395454A1 (en) * | 2019-12-02 | 2022-12-15 | Chiesi Farmaceutici S.P.A. | Stainless steel can for pressurised metered dose inhalers |
IL294804A (en) * | 2020-01-28 | 2022-09-01 | Chiesi Farm Spa | Inhalers with a measured dose under pressure containing the composition of pharmacy buffers |
WO2021165348A1 (fr) * | 2020-02-20 | 2021-08-26 | Chiesi Farmaceutici S.P.A. | Inhalateurs doseurs sous pression comprenant une formulation pharmaceutique tamponnée |
CN115989032A (zh) | 2020-07-31 | 2023-04-18 | 化学研究有限公司 | 用于吸入施用的组合疗法 |
US20230277451A1 (en) * | 2020-10-09 | 2023-09-07 | Chiesi Farmaceutici S.P.A. | A pharmaceutical formulation for pressurised metered dose inhaler |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2956062A (en) | 1959-02-26 | 1960-10-11 | Robins Co Inc A H | Esters of amino alcohols |
IT1317720B1 (it) | 2000-01-07 | 2003-07-15 | Chiesi Farma Spa | Dispositivo per la somministrazione di aerosol dosati pressurizzati inpropellenti idrofluoroalcani. |
GB0008660D0 (en) | 2000-04-07 | 2000-05-31 | Arakis Ltd | The treatment of respiratory diseases |
CZ303833B6 (cs) | 2000-05-22 | 2013-05-22 | Chiesi Farmaceutici S.P.A. | Aerosolový prostredek |
EP1321159A1 (fr) | 2001-12-21 | 2003-06-25 | CHIESI FARMACEUTICI S.p.A. | Dispositif d'actionnement pour inhalateur doseur pressurisé avec orifices percés par laser |
JP4819699B2 (ja) | 2004-02-06 | 2011-11-24 | メダ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディト ゲゼルシャフト | 喘息及びcopdの長期間の治療のための抗コリン作用薬及びグルココルチコイドの組合せ剤 |
GB0410399D0 (en) | 2004-05-10 | 2004-06-16 | Arakis Ltd | The treatment of respiratory disease |
GB0411056D0 (en) | 2004-05-18 | 2004-06-23 | Novartis Ag | Organic compounds |
WO2006105401A2 (fr) | 2005-03-30 | 2006-10-05 | Schering Corporation | Medicaments et procedes de combinaison d'un anticholinergique, un corticosteroide, et un agoniste beta a action prolongee |
GB0523653D0 (en) | 2005-11-21 | 2005-12-28 | Novartis Ag | Organic compounds |
GB0523655D0 (en) | 2005-11-21 | 2005-12-28 | Novartis Ag | Organic compounds |
GB0523654D0 (en) | 2005-11-21 | 2005-12-28 | Novartis Ag | Organic compounds |
GB0523656D0 (en) | 2005-11-21 | 2005-12-28 | Novartis Ag | Organic compounds |
DK2515855T6 (da) * | 2009-12-23 | 2023-06-06 | Chiesi Farm Spa | Kombinationsterapi til COPD |
WO2014033057A1 (fr) | 2012-08-29 | 2014-03-06 | Chiesi Farmaceutici S.P.A. | Dispositif d'inhalation d'aérosol |
RU2015154720A (ru) | 2013-05-22 | 2017-06-27 | Перл Терапьютикс, Инк. | Композиции, способы и системы для респираторной доставки трех или более активных средств |
ES2666905T4 (es) * | 2013-12-30 | 2018-06-07 | Chiesi Farmaceutici S.P.A. | Composición en solución para aerosol estable presurizada de una combinación de bromuro de glicopirronio y formoterol |
TN2016000261A1 (en) * | 2013-12-30 | 2017-10-06 | Chiesi Farm Spa | Stable pressurised aerosol solution composition of glycopyrronium bromide and formoterol combination. |
US10098837B2 (en) | 2016-07-28 | 2018-10-16 | Chiesi Farmaceutici S.P.A. | Combination therapy for COPD |
-
2017
- 2017-07-28 US US15/663,364 patent/US10098837B2/en active Active
- 2017-08-17 SG SG11201900471VA patent/SG11201900471VA/en unknown
- 2017-08-17 EA EA201990514A patent/EA201990514A1/ru unknown
- 2017-08-17 MA MA45984A patent/MA45984B1/fr unknown
- 2017-08-17 ES ES17758473T patent/ES2961242T3/es active Active
- 2017-08-17 NZ NZ750214A patent/NZ750214A/en unknown
- 2017-08-17 CA CA3029481A patent/CA3029481A1/fr active Pending
- 2017-08-17 PL PL17758473.7T patent/PL3500241T3/pl unknown
- 2017-08-17 CN CN201780049986.3A patent/CN109562061A/zh active Pending
- 2017-08-17 BR BR112019003173A patent/BR112019003173A2/pt unknown
- 2017-08-17 EP EP17758473.7A patent/EP3500241B1/fr active Active
- 2017-08-17 DK DK17758473.7T patent/DK3500241T3/da active
- 2017-08-17 WO PCT/EP2017/070850 patent/WO2018033598A1/fr active Application Filing
- 2017-08-17 RS RS20231015A patent/RS64751B1/sr unknown
- 2017-08-17 GE GEAP201715023A patent/GEP20227418B/en unknown
- 2017-08-17 FI FIEP17758473.7T patent/FI3500241T3/fi active
- 2017-08-17 SI SI201731458T patent/SI3500241T1/sl unknown
- 2017-08-17 KR KR1020197004574A patent/KR102440850B1/ko active IP Right Grant
- 2017-08-17 MD MDE20190710T patent/MD3500241T2/ro unknown
- 2017-08-17 AU AU2017314153A patent/AU2017314153B2/en active Active
- 2017-08-17 LT LTEPPCT/EP2017/070850T patent/LT3500241T/lt unknown
- 2017-08-17 JP JP2019530539A patent/JP7384666B2/ja active Active
- 2017-08-17 HU HUE17758473A patent/HUE064623T2/hu unknown
- 2017-08-17 PT PT177584737T patent/PT3500241T/pt unknown
- 2017-08-17 UA UAA201902491A patent/UA123231C2/uk unknown
- 2017-08-17 MX MX2019001587A patent/MX2019001587A/es unknown
- 2017-08-17 HR HRP20231729TT patent/HRP20231729T1/hr unknown
-
2019
- 2019-01-14 ZA ZA2019/00239A patent/ZA201900239B/en unknown
- 2019-02-03 IL IL264612A patent/IL264612B2/en unknown
- 2019-02-14 PH PH12019500315A patent/PH12019500315A1/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA45984B1 (fr) | Polytherapie pour la copd | |
EA201691375A1 (ru) | (2s)-n-[(1s)-1-циано-2-фенилэтил]-1,4-оксазепан-2-карбоксамиды в качестве ингибиторов дипептидилпептидазы i | |
MX2021004431A (es) | Procesos novedosos. | |
MA41013B1 (fr) | Compositions comprenant des souches bactériennes | |
SA518400356B1 (ar) | مثبطات الأرجيناز واستخداماتها العلاجية | |
WO2017011820A3 (fr) | Peptides inhibiteurs du récepteur de l'interleukine-23 et leur utilisation pour traiter des maladies inflammatoires | |
EA201990226A1 (ru) | Способы и композиции для лечения миелофиброза | |
PH12018502109A1 (en) | Medicine obtained by combining fxr agonist and arb | |
EA201990424A1 (ru) | Спиролактамовые модуляторы nmda-рецептора и их применение | |
EA201990428A1 (ru) | Спиролактамовые модуляторы nmda-рецептора и их применение | |
EA201800499A1 (ru) | Ингибитор тирозинкиназы для лечения амиотрофного латерального склероза, композиция, лекарственное средство, набор | |
TN2019000033A1 (fr) | Agents thérapeutiques pour maladies neurodégénératives | |
MA55799A (fr) | Polythérapies comprenant de l'aprémilast et des inhibiteurs de tyk2 | |
EA201690284A1 (ru) | Композиции и терапевтические способы для ускоренного регресса бляшки | |
PH12016501371A1 (en) | Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same | |
MX2016014696A (es) | Combinaciones de formoterol y budesonida para el tratamiento de enfermedad pulmonar obstructiva cronica. | |
EA201990095A1 (ru) | КОНДЕНСИРОВАННЫЕ ТИОФЕНОВЫЕ ПРОИЗВОДНЫЕ, ПРИЕМЛЕМЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ NAPI-IIb | |
MX2019007107A (es) | Anticuerpo anti-adrenomedulina (adm) o fragmento de anticuerpo anti-adm o supercontigo sin ig anti-adm para su uso en intervencion y terapia de congestion en un paciente con necesidad del mismo. | |
PH12017501829A1 (en) | Pharmaceutical formulations | |
IL270927B (en) | fused 5,6 bicyclic compounds and compounds for the treatment of parasitic diseases | |
MX2019015280A (es) | Composiciones de estatinas y metodos para su uso en el tratamiento de sinucleinopatias. | |
MX2020009305A (es) | Uso de un anticuerpo anti-p-selectina. | |
MA39833B1 (fr) | Nouvelle utilisation du n,n-bis-2-mercaptoéthyl isophtalamide | |
CL2020001961S1 (es) | Inhalador. (divisional solicitud 201902186) | |
MA55781A (fr) | Polythérapies comprenant de l'aprémilast et des inhibiteurs de tyk2 |